Legal & General Group
ARTV icon

Legal & General Group’s Artiva Biotherapeutics ARTV Stock Holding History

Legal & General Group’s Portfolio ARTV Stock Details ARTV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.49K Buy
+566
New +$5.16K ﹤0.01% 3370
2025
Q2 		– Sell
-2,018
Closed -$6.05K – 3574
2025
Q1 		$6.05K Buy
2,018
+625
+45% +$3.37K ﹤0.01% 3251
2024
Q4 		$14K Hold
1,393
– – ﹤0.01% 3160
2024
Q3 		$21.5K Buy
+1,393
New +$16.1K ﹤0.01% 3022

Other funds holding ARTV

RA Capital Management
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $39B AUM 18.55% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return

Legal & General Group's ARTV Position: Q2 2026 in Review

Legal & General Group opened a new position in Artiva Biotherapeutics (ARTV) in Q2 2026: 566 shares worth $5.49K. The stake represents ﹤0.01% of the portfolio and ranks #3370 among its holdings. This is a return to the name: Legal & General Group previously reported a position in ARTV as recently as Q1 2025.

Legal & General Group first reported a position in ARTV in Q3 2024 and has held it in 4 quarters since. The position peaked at $21.5K in Q3 2024. 72 funds tracked by Wall St. Rank hold ARTV as of Q2 2026.

  • Legal & General Group held 566 shares of Artiva Biotherapeutics worth $5.49K as of Q2 2026.
  • Artiva Biotherapeutics was a new Legal & General Group position in Q2 2026.
  • Artiva Biotherapeutics made up ﹤0.01% of Legal & General Group's portfolio in Q2 2026, its #3370 holding.
  • Legal & General Group first reported a position in Artiva Biotherapeutics in Q3 2024 and has held it in 4 quarters since.
  • Legal & General Group's Artiva Biotherapeutics position peaked at $21.5K in Q3 2024.
  • 72 funds tracked by Wall St. Rank held Artiva Biotherapeutics as of Q2 2026.

Based on Legal & General Group's 13F filing for Q2 2026, filed 14 Aug 2026.